M
Mirum Pharmaceuticals, Inc. (MIRM)
NGM – Real vaqt narxi. Valyuta: USD
88.44
-0.44 (-0.50%)
Yopilishda: Mar 27, 2026, 4:00 PM EDT
88.44
0.00 (0.00%)
Bozordan keyin: Mar 27, 2026, 4:34 PM EDT
Aksiya tahlili uchun eng kuchli vositalarga ega bo'ling
NGM – Real vaqt narxi. Valyuta: USD
88.44
-0.44 (-0.50%)
Yopilishda: Mar 27, 2026, 4:00 PM EDT
88.44
0.00 (0.00%)
Bozordan keyin: Mar 27, 2026, 4:34 PM EDT
Mirum Pharmaceuticals, Inc., biotexnologiya kompaniyasi, nogironlikka olib keluvchi kam uchraydigan va etim kasalliklar uchun yangi davolash usullarini ishlab chiqish va tijoratlashtirishga qaratilgan. Uning yetakchi mahsulot nomzodi LIVMARLI (maralixibat) hisoblanadi, bu og'iz orqali yuboriladigan va minimal darajada so'riladigan ichakdagi o't kislotasi tashuvchisi (IBAT) ingibitori bo'lib, AQSh va xalqaro miqyosda Alagille sindromi bilan og'rigan bemorlarda xolestatik qichishishni davolash uchun tasdiqlangan. Kompaniya, shuningdek, o't kislotasi sintezining buzilishi bo'lgan bolalar va kattalar bemorlarni davolash uchun, shuningdek, peroksizom buzilishlari, shu jumladan peroksizom biosintezi buzilishi - Zellweger spektr buzilishi va Smith-Lemli-Opitz sindromi bilan og'rigan bemorlarni qo'shimcha davolash uchun tasdiqlangan xol kislotasi kapsulasi Cholbamni tijoratlashtirish bilan shug'ullanadi; va safro pufagidagi rentgen nurlarini o'tkazmaydigan toshlarni davolash uchun tasdiqlangan va serebrotendinoz kstantomatozni davolash uchun ishlab chiqilayotgan tabletka Chenodal. Mening kompaniyam shuningdek, xolestatik jigar kasalliklari bo'lgan kattalar bemorlarni davolash uchun 2b bosqichdagi klinik sinovdan o'tayotgan og'iz orqali yuboriladigan va minimal darajada so'riladigan IBATni inhibe qilish uchun mo'ljallangan Volixibatni; 2-bosqich klinik sinovdan o'tayotgan surunkali HDV infektsiyasini davolash uchun Brelovitugni; va FXSni davolash uchun 2-bosqich klinik tadqiqotida bo'lgan MRM-3379ni ishlab chiqadi. Kompaniya Shire International GmbH bilan hamkorlik shartnomasiga ega; Pfizer Inc. bilan litsenziya shartnomasi; Sanofi-Aventis Deutschland GmbH; Novartis Pharma AG; Lonza Ltd.; Enthorin Therapeutics, LLC va Dart Neuroscience LLC; Asklepion Pharmaceuticals, LLC bilan aktiv sotib olish shartnomasi; LGM Pharma bilan litsenziya va ishlab chiqarish shartnomasi; va Travere Therapeutics, Inc. bilan aktiv sotib olish shartnomasi. Kompaniya 2018 yilda tashkil etilgan va shtab-kvartirasi Kaliforniyaning Foster City shahrida joylashgan.
| Ism | Lavozim |
|---|---|
| Dr. Jean-Luc Girardet Ph.D. | Chief Technical Officer |
| Dr. Joanne M. J. Quan M.D. | Chief Medical Officer |
| Meredith Kiernan | Senior Director of Global Corporate Communications |
| Mr. Andrew McKibben | Senior Vice President, Strategic Finance & Investor Relations |
| Mr. Christopher Peetz | CEO & Director |
| Mr. Douglas T. Sheehy J.D. | Chief Legal Officer |
| Mr. Eric H. Bjerkholt M.B.A., M.S. | Chief Financial Officer |
| Sana | Turi | Hujjat |
|---|---|---|
| 2026-01-29 | D | |
| 2026-01-26 | 8-K | d35336d8k.htm |
| 2026-01-12 | 8-K | mirm-20260112.htm |
| 2025-12-19 | 8-K | d53644d8k.htm |
| 2025-12-08 | 8-K | d46722d8k.htm |
| 2025-11-17 | 8-K | mirm-20251117.htm |
| 2025-11-04 | 10-Q | mirm-20250930.htm |
| 2025-09-09 | S-8 | mirm-sx820250909.htm |
| 2025-08-12 | S-3ASR | d74930ds3asr.htm |
| 2025-08-06 | 10-Q | mirm-20250630.htm |
| Mr. Peter Radovich M.B.A., Ph.D. |
| COO & President |
| Ms. Erin Campany | Chief People Officer |
| Ms. Lara Longpre MBA, MSC | Chief Development Officer |